Ontario's leading advocate for the life sciences sector
Zucara Therapeutics, a diabetes life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, recently announced that it has dosed the first patient in its Phase 2a trial of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes.
Zucara Therapeutics is an OBIO® member and presented at the OBIO® Investment Summit.
Paradox Immunotherapeutics, a biotech company based in Toronto, has been announced the winner of Biotechnology Innovation Organization’s (BIO) 2023 Start-Up Stadium! Paradox is focused on the development of monoclonal antibody (mAb) therapies for the treatment of protein misfolding diseases, including amyloidosis.
Congratulations to Paradox and to all the finalists! We are proud to share that Paradox is an OBIO® member and an alumnus of our BDSP™, CAAP®, H2BB™ and WiHI programs.
The Ontario Brain Institute recently announced $600,000 in funding to the 2023 NERVE cohort, a group of six entrepreneurs funded through Canada's single largest award for early-stage neurotechnology companies. The Neurotech Entrepreneurship to Validate Emerging Innovations (NERVE) program provides $100,000 to awarded Canadian-based entrepreneurs, in addition to 12 months of training and mentorship opportunities.
Congratulations to the NERVE cohort and special shout-out to OBIO® member, Foqus Technologies, that is also a part of our current CAAP® cohort.
Check out how Retispec’s AI platform can detect early signs of Alzheimer’s from a simple eye exam in this article featured in the MaRS newsletter. Retispec’s innovative technology can transform Alzheimer’s disease screening by making it easily accessible and timely.
Retispec is an OBIO® member, an alumnus of the BDSP™, CAAP®, H2BB™, HealthMINT™ and WiHI programs and presented at the OBIO® Investment Summit.
Nabanita Nawar, co-founder/CEO of HDAX Therapeutics, is the winner of BIOTECanada’s Gold Leaf Award for Next Generation Leadership. The awards recognize the remarkable individuals and companies who have made significant contributions to the biotech industry in Canada. The 2023 Gold Leaf Awards ceremony will be held on September 27 at the National Arts Centre in Ottawa during Global Biotech Week (September 24 – 30).
HDAX Therapeutics is a drug discovery start-up developing targeted therapeutics platform for the safe and efficacious treatment of HDAC-driven pathologies such as neuropathies and neurodegenerative disorders.
HDAX Therapeutics is an OBIO® member, an alumnus of the BDSP™ and WiHI programs and presented at the OBIO® Investment Summit.
Epineuron, a clinical-stage nerve care company, recently announced that it has successfully enrolled the first patient in the company’s pivotal trial, REGAIN™. This is a huge milestone for Epineuron and a step towards advancing better care for the treatment of injured peripheral nerves.
Epineuron is an alumnus of OBIO’s BDSP™, CAAP® , H2BB™ and WiHI programs.
Liberum, a seed-stage venture focused on speeding up enzyme and antibody discovery via its state-of-the-art proprietary cell-free protein synthesis platform, has raised a $1.8 million seed round to increase its production capacity, make additions to its team and expand its suite of available proteins for customers.
Liberum presented at the Early Technology Showcase at the OBIO® Investment Summit.
MaRS recently announced phase three of its partnership with SCALE AI, the federal artificial intelligence (AI) supercluster, to support the growth and commercialization of 12 promising Canadian companies with supply chain solutions. These up-and-coming ventures will join the Supply AI program at the Toronto-based innovation hub to refine their products, create jobs, grow their brand awareness and attract investment.
Congratulations to the twelve selected ventures! We are pleased to share that Empower Health, one of the ventures, is an OBIO®-affiliated company. They are an alumnus of OBIO’s BDSP and WiHI programs.
The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, recently announced the 2023 Prix Galien USA Award nominees for different categories. Winners will be announced during the Prix Galien USA Forum on October 26 in New York City.
Congratulations to Flosonics Medical, an OBIO® member and an alumnus of all OBIO® programs, on being nominated in the 'Best Medical Technology' category, and to other nominees.
Communitech’s Fast Track Health collaborative and its partners have identified ten Canadian tech firms with scaleable innovations to help overcome the biggest hurdles facing today's healthcare systems. The selected companies will pitch at the Future of Health Solutions Showcase virtual event on September 14.
OBIO® is a strategic partner in Communitech's Fast Track Health program.
Congratulations to the selected companies! We are thrilled to share that five of the selected companies, AIMA Laboratories, Foqus Technologies, Hyivy Health, Llif Healthcare and Topology Health are OBIO® member companies!
CryoStasis, a company that brings a combination of chemistry, biochemistry and cooling processes to provide cell preservation that has been proven in nature, recently announced that it has secured Seed financing to pursue its plan to develop next generation sub-zero unfrozen cryopreservation solutions. The company’s first financing round was led by Genesys Capital with significant participation from individual investors and the management team.
Cryostasis is an OBIO® member.
Novo Nordisk, a leading leading global healthcare company, recently announced the acquisition of Inversago Pharma, a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.
Inversago presented at the OBIO® Investment Summit.
FluidAI Medical, a Canadian medical technology company that uses AI to aid with the early detection of postoperative leaks, recently launched their revolutionary AI-powered patient monitoring platform - Stream™ Platform. Through the use of the platform, surgeons have the potential to make a more accurate and timely diagnosis of postoperative leaks which can lead to better treatment outcomes and an improved quality of life for the patients.
Fluid AI is an OBIO® member and an alumnus of all OBIO® programs.
VoxNeuro, which develops software that measures brain performance, has raised $4.5 million CAD in all-equity funding as the company looks to expand across the U.S. With this funding, VoxNeuro plans to accelerate its product development and operational model as it scales clinical installations across the U.S.
VoxNeuro is an alumnus of HealthMINT™ program and presented at the OBIO® Investment Summit.
Vive Crop Protection has been selected for the inaugural cohort of the Government of Canada’s Global Hypergrowth Project (GHP), an innovative initiative that will support growing organizations to become Canada’s next anchor firms. As a GHP firm, Vive will be supported by Innovation, Science, and Economic Development Canada in areas such as funding, international expansion, talent acquisition, navigation of federal regulations, access to procurement projects, mentorship and expertise.
Vive Crop Protection is an alumnus of the BDSP™ and H2BB™ programs.
Vital Biosciences recently introduced VitalOne, their revolutionary blood testing technology on plenary stage at the American Association of Clinical Chemistry (AACC) Annual Meeting and announced total funding of $48 million. The innovative solution reimagines point-of-care testing through VitalOne to create a world where patients will not need to take additional time off from work, travel between their primary care doctor and a lab, or wait for days to discuss their results with their healthcare provider.
Vital Biosciences is an alumnus of the BDSP™ and CAAP® programs.
Management of mechanically ventilated patients can be complex due to the difficulty in directly assessing the impacts to the heart and lung following clinical interventions. Rostrum Medical recently announced the publication of initial validation results of its VQm® System, designed and developed to address these challenges in patient management.
Rostrum Medical is an EAHN™ company and presented at the OBIO® Investment Summit.
Retispec’s AI-driven retinal scan was featured in Global News. The feature showcased an initiative led by the Davos Alzheimer’s Collaborative to assess the feasibility of utilizing RetiSpec’s AI technology in community-based settings for Alzheimer’s disease screening.
Retispec is an OBIO® member, an alumnus of the BDSP™, CAAP®, H2BB™, HealthMINT™ and WiHI programs and presented at the OBIO® Investment Summit.
ImmunoBiochem recently announced a multi-target license and option agreement with ImmunoGen to advance novel, first-in-class antibody drug conjugates. The collaboration will combine ImmunoGen's proprietary linker and payload technologies with ImmunoBiochem's antibodies directed against specific targets.
ImmunoBiochem is an alumnus of the CAAP® program and presented at the OBIO® Investment Summit.
SheBoot, the investment-ready bootcamp that prepares women founders to pitch their business and secure investment, recently announced becoming a national non-profit organization. Building on three years of impact, the program founded in Canada’s Capital is now scaling more broadly to help fuel the growth and success of women founders across the country.
